J. Morris

发表

Cycloalkylpyranones and cycloalkyldihydropyrones as HIV protease inhibitors: exploring the impact of ring size on structure-activity relationships.

W. Howe, D. Anderson, K. Chong, 1996, Journal of medicinal chemistry.

Synthesis and biological evaluation of antiplatelet 2-aminochromones.

D. Wishka, S. Bisaha, J. Morris, 1993, Journal of medicinal chemistry.

Use of medium-sized cycloalkyl rings to enhance secondary binding: discovery of a new class of human immunodeficiency virus (HIV) protease inhibitors.

W. Howe, B. Finzel, K. Watenpaugh, 1995, Journal of medicinal chemistry.

On the stereochemistry and biosynthesis of lipoxin B.

M. Hamberg, C. Serhan, B. Samuelsson, 1986, Proceedings of the National Academy of Sciences of the United States of America.

Substituent effects on the antibacterial activity of nitrogen-carbon-linked (azolylphenyl)oxazolidinones with expanded activity against the fastidious gram-negative organisms Haemophilus influenzae and Moraxella catarrhalis.

Joel Morris, D. Anderson, M. Genin, 2000, Journal of medicinal chemistry.

Synthesis of lipoxin B.

D. Wishka, J. Morris, 1986, Advances in prostaglandin, thromboxane, and leukotriene research.

An E-box Region within the Prostaglandin Endoperoxide Synthase-2 (PGS-2) Promoter Is Required for Transcription in Rat Ovarian Granulosa Cells*

J. Richards, J. Morris, 1996, The Journal of Biological Chemistry.

Pyrimidine thioethers: a novel class of HIV-1 reverse transcriptase inhibitors with activity against BHAP-resistant HIV.

R. Nugent, L. Kopta, R. Olmsted, 1998, Journal of medicinal chemistry.

(-)-6-Chloro-2-[(1-furo[2, 3-c]pyridin-5-ylethyl)thio]-4-pyrimidinamine, PNU-142721, a new broad spectrum HIV-1 non-nucleoside reverse transcriptase inhibitor.

W. L. White, R. Nugent, L. Kopta, 1998, Journal of medicinal chemistry.

Structure-based design of nonpeptidic HIV protease inhibitors: the sulfonamide-substituted cyclooctylpyramones.

K D Watenpaugh, W. Howe, D. Anderson, 1997, Journal of medicinal chemistry.

Structure-based design of HIV protease inhibitors: sulfonamide-containing 5,6-dihydro-4-hydroxy-2-pyrones as non-peptidic inhibitors.

W. Howe, K. Watenpaugh, F. Schwende, 1996, Journal of medicinal chemistry.

Dopaminergic and serotonergic activities of imidazoquinolinones and related compounds.

D. Evans, W. E. Hoffmann, C. Chidester, 1992, Journal of medicinal chemistry.

Structure-based design of nonpeptidic HIV protease inhibitors from a cyclooctylpyranone lead structure.

K D Watenpaugh, W. Howe, K. Watenpaugh, 1995, Journal of medicinal chemistry.

Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.

Joel Morris, D. B. Evans, S. Sharma, 1996, Journal of medicinal chemistry.

2-Aminochromones block human platelet aggregation by inhibiting cyclic AMP-dependent phosphodiesterase leading to reduced platelet phospholipase C activity.

C. Benjamin, R. Gorman, D. Wishka, 1993, Journal of Pharmacology and Experimental Therapeutics.

Cholinergic activity of acetylenic imidazoles and related compounds.

R. Collins, R. Russell, C. Chidester, 1991, Journal of medicinal chemistry.

Receptor antagonism of leukotriene B4 myotropic activity by the 2,6 disubstituted pyridine analog U-75302: characterization on lung parenchyma strips.

F. Fitzpatrick, D. Wishka, J. Morris, 1989, Journal of lipid mediators.